drugset / Trial / NCT00208234

Effect of Xolair on Airway Hyperresponsiveness

NCT00208234

Phase 4 Unknown 22 enrolled Creighton University Genentech, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if Xolair can reduce the abnormal increase in limitation to airflow in patients with asthma in a relatively short time period. Another purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of an asthmatic patient in the same time period.

Timeline

Start
2004-01
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody 0.016 mg/kg

Indications